Clinical trial · Interventional
Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects
Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects
NCT02054754CI-TRIAL-00022332completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test the safety and observe the pharmacokinetics (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy male subjects following a single oral dose.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Pharmacokinetics | — | UNRESOLVED | — |
| Safety | — | UNRESOLVED | — |
| Tolerability | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexanabinol Dose Level 1 | Drug | — | UNRESOLVED |
| Dexanabinol Dose Level 2 | Drug | — | UNRESOLVED |
| Dexanabinol Dose Level 3 | Drug | — | UNRESOLVED |
| Dexanabinol Dose Level 4 | Drug | — | UNRESOLVED |
| Dexanabinol Dose Level 5 | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- EXPERIMENTAL
- label
- Dexanabinol Dose Level 1
- description
- Single oral dose of dexanabinol
- interventionNames
- Drug: Dexanabinol Dose Level 1
- type
- EXPERIMENTAL
- label
- Dexanabinol Dose Level 2
- description
- Single oral dose of dexanabinol
- interventionNames
- Drug: Dexanabinol Dose Level 2
- type
- EXPERIMENTAL
- label
- Dexanabinol Dose Level 3
- description
- Single oral dose of dexanabinol
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Healthy males aged 18 to 45 years * Body mass index 18.0 to 32.0 kg/m2, or if outside the range, considered not clinically significant by the investigator Exclusion Criteria: * Participation in a clinical research study within the previous 3 months * Current smokers and those who have smoked within the last 12 months * History of any drug or alcohol abuse in the past 2 years
References
Publications (0)
Data not yet available
No reference posted for this study.